Seeing Is Believing
Currently out of the existing stock ratings of Scott Schoenhaus, 75 are a BUY (92.59%), 6 are a HOLD (7.41%).
Analyst Scott Schoenhaus, currently employed at KEYBANK, carries an average stock price target met ratio of 41.97% that have a potential upside of 18.98% achieved within 79 days. Previously, Scott Schoenhaus worked at STEPHENS.
Scott Schoenhaus’s has documented 154 price targets and ratings displayed on 17 stocks. The coverage is on Healthcare, Technology sectors.
Most recent stock forecast was given on ABCL, Abcellera Biologics at 11-Jul-2024.
Analyst best performing recommendations are on BNFT (BENEFITFOCUS).
The best stock recommendation documented was for RXRX (RECURSION PHARMACEUTICALS) at 7/13/2023. The price target of $15 was fulfilled within 6 days with a profit of $2.56 (20.58%) receiving and performance score of 34.3.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$10
$0.96 (10.62%)
$20
18 days ago
10/13 (76.92%)
$0.89 (9.77%)
38
Hold
$10
$0.96 (10.62%)
18 days ago
1/3 (33.33%)
$0.89 (9.77%)
3
Hold
$9
$-0.04 (-0.44%)
$16
1 months 9 days ago
15/19 (78.95%)
$1.69 (23.12%)
158
Buy
$10
$0.96 (10.62%)
$25
1 months 29 days ago
3/8 (37.5%)
$2.51 (33.51%)
29
Hold
$10
$0.96 (10.62%)
$23
2 months 3 days ago
19/28 (67.86%)
$2.05 (25.79%)
180
Which stock is Scott Schoenhaus is most bullish on?
Which stock is Scott Schoenhaus is most reserved on?
What Year was the first public recommendation made by Scott Schoenhaus?